Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Li

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Breast Cancer Research and Treatment|June 13, 2024
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practiceManali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|December 19, 2017
Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancerPeter Bankhead, José A Fernández, Darragh G McArt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 7, 2023
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancerBreana L Hill, Ryon P Graf, Kunal Shah, et al.
JCO Precision Oncology|July 6, 2023
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessJulia C F Quintanilha, Michael H Storandt, Ryon P Graf, et al.
JAMA Network Open|January 23, 2023
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational BurdenJulia C F Quintanilha, Ryon P Graf, Virginia A Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
JCO Precision Oncology|July 12, 2022
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesAmado J Zurita, Ryon P Graf, Guillermo Villacampa, et al.
JAMA Network Open|December 27, 2023
Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational BurdenAndrea Necchi, Philippe E Spiess, Tiago Costa de Padua, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Breast Cancer Research and Treatment|June 13, 2024
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practiceManali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|December 19, 2017
Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancerPeter Bankhead, José A Fernández, Darragh G McArt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 7, 2023
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancerBreana L Hill, Ryon P Graf, Kunal Shah, et al.
JCO Precision Oncology|July 6, 2023
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessJulia C F Quintanilha, Michael H Storandt, Ryon P Graf, et al.
JAMA Network Open|January 23, 2023
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational BurdenJulia C F Quintanilha, Ryon P Graf, Virginia A Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2022
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate CancerUmang Swami, Ryon P Graf, Roberto H Nussenzveig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World PracticeDebra L Richardson, Julia C F Quintanilha, Natalie Danziger, et al.
JCO Precision Oncology|July 12, 2022
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesAmado J Zurita, Ryon P Graf, Guillermo Villacampa, et al.
JAMA Network Open|December 27, 2023
Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational BurdenAndrea Necchi, Philippe E Spiess, Tiago Costa de Padua, et al.
Pageof 4